PARI PHARMA WORLDWIDE

Our vision is to improve the lives of those affected by respiratory diseases and those who provide care to them.

Last year, we celebrated 100 years of innovation in the field of aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas.
science and inhalation technology.

PARI is made up of a worldwide network of companies, each with a specific focus in developing or improving aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas.
therapies. We dominate the field of liquid drug aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas.
delivery by nebulizer.

PARI products are considered the “Gold Standard” for new nebulized medications being developed and used in clinical trials. Pharmaceutical companies with approved medications using PARI products include:

  • Accuneb® (Dey) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • Brovana® (Sepracor) for COPD
  • Cayston® (Gilead) for CF
  • DuoNeb® (Dey) for COPD, asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • Perforomist® (Dey) for COPD
  • Pulmicort® Respules (AstraZeneca) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.
  • Pulmozyme® (Genentech) for cystic fibrosis cystic fibrosis
    Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions.
  • TOBI® (Novartis) for cystic fibrosis cystic fibrosis
    Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions.
  • Xopenex® (Sepracor) for asthma asthma
    Asthma is a common chronic inflammatory airway disease, characterized by variable and recurring symptoms, reversible airflow obstruction and bronchospasm.

Currently, PARI products are being used in 15 additional clinical trials in the development of new nebulized treatments.